It does not have any agonist or antagonist activity towards FXR and VDR, but it suppresses lipogenesis and has potential in cholangitis and obesity treatment [127,128,129]. This evidence concerns the gene NR1H4 and obesity due to melanocortin 4 receptor deficiency.